作者
Gabriel N. Hortobágyi,Aleksandra Łacko,Joohyuk Sohn,F. Melo Cruz,Manuel Ruíz Borrego,Alexey Manikhas,Yeon H. Park,Daniil Stroyakovskiy,Denise A. Yardley,C.-S. Huang,P.A. Fasching,J. Crown,A. Bardia,S. Chia,Sun Im,M. Martín,Sherene Loi,B. Xu,Sara A. Hurvitz,Carlos H. Barrios,M. Untch,R Moroose,F. Visco,Federico Parnizari,J.P. Zarate,Zheng Li,Simon Waters,A. Chakravartty,D. Slamon
摘要
NATALEE assessed efficacy and tolerability of 3 years of adjuvant ribociclib plus NSAI compared with a nonsteroidal aromatase inhibitor (NSAI) alone in a broad population of patients with HR+/HER2- early breast cancer, including a select group without nodal involvement. This is the final preplanned analysis of invasive disease-free survival (iDFS).